Overview

This trial is active, not recruiting.

Condition telangiectasia, hereditary hemorrhagic
Sponsor Imperial College London
Start date September 2008
End date August 2020
Trial size 50 participants
Trial identifier NCT00733655, IC/CLS5

Summary

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to obtain small skin samples from patients with HHT in order to analyze the samples using histological methods, and study the properties of vascular endothelial cells derived from patients. We hypothesize that these cells will show altered growth, migration, and protein synthetic differences when compared to normal endothelial cells, which may be confirmed in single time point analyses in histological samples. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients with Hereditary Haemorrhagic Telangiectasia Exclusion Criteria: - Unable to provide informed consent

Additional Information

Principal investigator Claire L Shovlin
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Imperial College London.